{"classes":[{"categories":[{"measurements":[{"comment":"NA = The value was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"18.3","upperLimit":"NA","value":"21.3"},{"comment":"NA = The value was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"12.0","upperLimit":"NA","value":"17.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"description":"DOR was defined as the time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer as defined in RECIST 1.1 per investigator assessment. The Kaplan-Meier method was used to estimate DOR, and the median DOR, along with 95% confidence intervals, was reported for each treatment group. If a participant had not had an event, duration was censored at the date of last adequate tumor assessment.\n\nCR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ribociclib 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)","id":"OG000","title":"Ribociclib + NSAI/Tamoxifen + Goserelin"},{"description":"Placebo daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days).","id":"OG001","title":"Placebo + NSAI/Tamoxifen+ Goserelin"}],"paramType":"MEDIAN","populationDescription":"Randomized participants with confirmed CR or PR as per investigator assessment","reportingStatus":"POSTED","timeFrame":"Up to approximately 29 months","title":"Duration of Response (DOR) by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}